Evaxion Posts Three-Year Data for Personalized Melanoma Vaccine EVX-01
Evaxion Biotech reports three-year follow-up data for EVX-01, its AI-designed personalized therapeutic vaccine for melanoma, extending durability evidence.
Topic
Melanoma
Topic
Melanoma
Final Melanoma Survival Data Headed to ESMO, Faron Confirms
Faron will present final melanoma survival data at the ESMO congress — a mature dataset that could shape advanced cutaneous melan…
Evaxion Reports Three-Year Data for Melanoma Vaccine EVX-01
Evaxion reports three-year data for melanoma vaccine EVX-01, a personalized neoantigen candidate; the disclosure headline omits s…
Evaxion Brings Three-Year EVX-01 Melanoma Data to ESMO 2026
Evaxion will present three-year Phase 2 follow-up on its personalized neoantigen vaccine EVX-01 in advanced melanoma at ESMO 2026…
Moderna and Merck Present Phase 3 Melanoma Data on Personalized Cancer Vaccine
Moderna and Merck present Phase 3 melanoma findings for their personalized mRNA cancer vaccine; endpoints, effect sizes and filin…
AAFP Publishes Melanoma Diagnosis and Treatment Guidance
The AAFP has published a clinical review, "Melanoma: Diagnosis and Treatment," guiding family physicians on lesion assessment, bi…
Second-Opinion Pathology Reviews Before Derm Surgery: A JAAD Look
A JAAD study published online October 17, 2026 measures how second-opinion pathology reviews before dermatologic surgery change c…
Hungarian Hospital Reports Shorter Melanoma Delays via Digital Pathway
A Hungarian hospital reports shorter melanoma care delays with a digital patient pathway system, though effect sizes and staging…
New Sunscreen Filter Reaches U.S. Shelves as Texas Reports Rising Melanoma
A new UV sunscreen filter has reached U.S. retail shelves just as melanoma rates climb in Texas, giving dermatologists a new coun…
Free Skin Cancer Screening Program Ends Its Run in Santa Barbara
A free skin cancer screening program is stopping in Santa Barbara, KSBY reports, ending no-cost early detection access for a high…